Animace načítání

Stránka se připravuje...

Přihlásit se Registrovat se
28 180 právních předpisů

Další údaje zde

Technická podpora

Poskytujeme technickou podporu zdarma

Zavolejte nám

+420 777 717 492

Plné znění - 32020R1182

  1. Úvodní strana
  2. Právní předpisy EU
  3. Plné znění - 32020R1182

Na co čekáte? Nečekejte už ani minutu.
Získejte přístup na tento text ještě dnes. Kontaktujte nás a my Vám obratem uděláme nabídku pro Vás přímo na míru.

Chci získat výhodný přístup

NAŘÍZENÍ XXXXXX V XXXXXXXXX XXXXXXXXX (EU) 2020/1182

xx xxx 19. xxxxxx 2020,

kterým xx xxx xxxxx xxxxxxxxxxxx xxxxxxxxxxx x xxxxxxxxx xxxxxxx xxxx xxxx 3 xxxxxxx VI xxxxxxxx Xxxxxxxxxx parlamentu x Xxxx (XX) x. 1272/2008 x xxxxxxxxxxx, označování x xxxxxx xxxxx a xxxxx

(Xxxx s xxxxxxxx xxx XXX)

XXXXXXXX KOMISE,

s xxxxxxx xx Xxxxxxx x xxxxxxxxx Xxxxxxxx xxxx,

x ohledem xx xxxxxxxx Xxxxxxxxxx xxxxxxxxxx x Xxxx (XX) x. 1272/2008 xx xxx 16. xxxxxxxx 2008 o xxxxxxxxxxx, xxxxxxxxxx x xxxxxx xxxxx x xxxxx, x změně a xxxxxxx xxxxxxx 67/548/XXX x 1999/45/XX a x změně xxxxxxxx (XX) x. 1907/2006&xxxx;(1), x zejména na xx. 37 odst. 5 uvedeného nařízení,

vzhledem x těmto důvodům:

(1)

Tabulka 3 x xxxxx 3 xxxxxxx XX xxxxxxxx (ES) x. 1272/2008 xxxxxxxx seznam xxxxxxxxxxxxxxx xxxxxxxxxxx a xxxxxxxx xxxxxxxxxxxx látek xx základě kritérií xxxxxxxxxxx x xxxxxxx 2 xx 5 xxxxxxx I xxxxxxxxx xxxxxxxx.

(2)

Xxxxxxxx agentuře xxx xxxxxxxx xxxxx („xxxxxxxx“) xxxx x xxxxxxx x xxxxxxx 37 xxxxxxxx (XX) x. 1272/2008 předloženy xxxxxx xx xxxxxxxx xxxxxxxxxxxxx xxxxxxxxxxx x xxxxxxxx xxxxxxxxx xxxxx x xxxxxxxxxxx nebo xxxxxxx xxxxxxxxxxxxxxx klasifikací x xxxxxxxx některých xxxxxx xxxxx. Xx xxxxxxx xxxxxxxxxx&xxxx;(2) k těmto xxxxxxx, xxxxx xxxxx Xxxxx pro xxxxxxxxxx xxxxx („XXX“) agentury, xxxxx x připomínek xxxxxxxxxxxx xxxxx, xx xxxxxx xxxxxx, xxxxxxxxxxxx xx zrušit harmonizované xxxxxxxxxxx a označení xxxxxxxxx xxxxx. Xxxxxxx xxxxxxxxxx výboru RAC xxxx:

—

xxxxxxxxxx ze xxx 8. června 2018 xxxxxxx xxxxxxxx xxxxxxx... %[X ≤ 70 %],

—

xxxxxxxxxx xx xxx 9. xxxxxx 2018 xxxxxxx xxxxxx x xxxxxxx xxxxxxx (x xxxxxxx < 3 μx,xxxxx &xx; 5 μx x xxxxxx xxxxx ≥ 3:1),

—

xxxxxxxxxx xx dne 8. xxxxxx 2018 xxxxxxx xxxxxxxxxxxxxxxxxxxxx, xxxxxxxxxx(xxxxx)xxxxxx,

—

xxxxxxxxxx xx xxx 8. června 2018 ohledně xxxx(2-xxxxxxxxxxxxx)xxxxxxxxxxx, 6-(2-xxxxxxxxxxxxx)-6-xxxxx-2,5,7,10-xxxxxxxx-6-xxxxxxxxxxxx,

—

xxxxxxxxxx xx dne 8. xxxxxx 2018 xxxxxxx dimethyl-disulfidu,

—

stanovisko xx xxx 8. června 2018 ohledně xxxxxxxxxxx xxxx,

—

xxxxxxxxxx xx xxx 30. xxxxxxxxx 2018 xxxxxxx xxx (N-hydroxy-N-nitrosocyklohexylaminato-O,O’)-mědi, xxx(X-xxxxxxxxxx-xxxxxxxxx-xxxxx)-xxxx, [Xx-XXX],

—

xxxxxxxxxx ze xxx 14. xxxx 2018 ohledně dioktyltin-dilaurátu, [1] stannanu, xxxxxxx-, xxx(xxxx xxxxxxx) xxxxxxxx [2],

—

xxxxxxxxxx ze xxx 30. xxxxxxxxx 2018 xxxxxxx xxxxxxx[xxx,x]xxxxxxxx, xxxxxxx[x,x]xxxxxx,

—

xxxxxxxxxx xx xxx 9. xxxxxx 2018 xxxxxxx xxxxxxxxxx (ISO), (1XX,2XX,5XX;1XX,2XX,5XX)-2-(4-xxxxxxxxxxx)-5-xxxxxxxxx-1-(1X-1,2,4-xxxxxxx-1-xxxxxxxx)xxxxxxxxxxxxxx,

—

xxxxxxxxxx xx xxx 8. xxxxxx 2018 xxxxxxx xxx(2-(2-xxxxxxxxxxxxx)xxxxx)xxxxxx, xxxxxxxxxx,

—

xxxxxxxxxx xx xxx 8. června 2018 xxxxxxx xxxxxxxxxxxxxx (XXX), (2RS,3RS)-1-(4-chlorofenyl)-4,4-dimethyl-2-(1H-1,2,4-triazol-1-yl)pentan-3-olu,

—

stanovisko ze xxx 8. xxxxxx 2018 xxxxxxx 2,2-xxx(xxxxxxxxxx)xxxxxx-1,3-xxxxx,

—

xxxxxxxxxx xx xxx 14. xxxx 2018 ohledně xxxxxxxxx, (2X)-3,7-xxxxxxxxxxxx-2,6-xxxx-1-xxx,

—

xxxxxxxxxx xx xxx 28. ledna 2019 ohledně 2-(4-xxxx-xxxxxxxxxxx)xxxxxxxxxxxxxxx,

—

xxxxxxxxxx xx dne 9. xxxxxx 2018 xxxxxxx XXXX-xxxxxxxxxx (XXX), X-xxxxx (4-xxxxx-2-xxxxxxxxxxxx)xxxxxxxxxxxxx, X-xxxxx 4-xxxxx-x-xxxxxxxxxxxxxxxxxxx,

—

xxxxxxxxxx xx xxx 9. xxxxxx 2018 xxxxxxx xxxxxxxxxx-xxxxxxx,

—

xxxxxxxxxx ze xxx 14. xxxx 2018 xxxxxxx 4-{[(6-xxxxxxxxxxxxx-3-xx)xxxxxx](2,2-xxxxxxxxxxxxx)xxxxx}xxxxx-2(5X)-xxx, xxxxxxxxxxxxxxx,

—

xxxxxxxxxx xx xxx 30. xxxxxxxxx 2018 ohledně xxxxxxxxxxxxx-xxxxxxx (XXX), xxxxxx 4- [(4,5-dihydro-3-methoxy-4-methyl-5-oxo-1H-1,2,4-triazol-1-yl)karbonylsulfamoyl]-5-methylthiofen-3-karboxylátu,

—

stanovisko ze xxx 9. xxxxxx 2018 ohledně X-(+)-xxxxxx xxxxxxxx, (2X)-2-xxxxxxxxxxxxxxxx kyseliny,

—

stanovisko xx xxx 9. xxxxxx 2018 xxxxxxx 2-xxxxxxxxxxxx-xxxxxxxx,

—

xxxxxxxxxx xx xxx 8. xxxxxx 2018 xxxxxxx xxxxxxxxxx xxxxxxxx …%,

—

xxxxxxxxxx xx xxx 14. září 2018 xxxxxxx xxxxxxx-X-(xxxxxxxxxxxxx)xxxxxxxxx, [xxxxxxxxxxx xxxxxxxx x xxxxxx-X-(xxxxxxxxxxxxx)xxxxxxxxx],

—

xxxxxxxxxx xx xxx 30. xxxxxxxxx 2018 xxxxxxx (xxxxx-XXX-xxxxx)xxxxxxxxxxx xxxxxxxxxx, cyklohexyl(hydroxy)diazen-1-oxidu, xxxxxxxx xxxx, [K-HDO],

—

stanovisko xx dne 14. xxxx 2018 xxxxxxx xxxxxxxxxxx-xxxxxxxxxxx, X-xxxxx-X,X-xxxxxxxxxxxxxxxxx-1-xxxxxxx-xxxxx-xxxxxxx, xxxxxxxxxxx-xxxxx-xxxxxxx [XXX],

—

xxxxxxxxxx ze xxx 9. xxxxxx 2018 xxxxxxx (2XX)-2-[4-(4-xxxxxxxxxxx)-2(xxxxxxxxxxxxxxx)xxxxx]-1-(1X-1,2,4-xxxxxxx-1-xx)xxxxxx-2-xxx, xxxxxxxxxxxxxxxxxxx,

—

xxxxxxxxxx xx xxx 30. xxxxxxxxx 2018 xxxxxxx xxxxxxxxxxxxxxxx (XXX), 1-(4-{4-[5-(2,6-xxxxxxxxxxxx)-4,5-xxxxxxx-1,2-xxxxxx-3-xx]-1,3-xxxxxxx-2-xx}xxxxxxxxx-1-xx)-2-[5-xxxxxx-3-(xxxxxxxxxxxxxxx)-1X-xxxxxxx-1-xx]xxxxxxxx,

—

xxxxxxxxxx xx dne 14. xxxx 2018 xxxxxxx xxxxxxxxx-xxxxx, (X-4)-xxx[1-(xxxxxxx-xxxxx-X)xxxxxxx-2(1X)-xxxxxxx-xxxxx-X]xxxxx,

—

xxxxxxxxxx ze xxx 30. listopadu 2018 xxxxxxx 3-chlor-4-(chlormethyl)-1-[3-trifluormethyl)fenyl]pyrrolidin-2-onu, xxxxxxxxxxxxxxx (ISO),

—

stanovisko xx xxx 30. xxxxxxxxx 2018 xxxxxxx 4,5-xxxxxxx-2-xxxxx-2X-xxxxxxxxxx-3-xxx, [XXXXX],

—

xxxxxxxxxx xx dne 8. xxxxxx 2018 xxxxxxx 2-methyl-1,2-benzothiazol-3(2H)-onu, [MBIT],

—

stanovisko xx xxx 30. xxxxxxxxx 2018 xxxxxxx 3-(xxxxxxxxxxxxx)-1-xxxxxx-X-(3‘,4’,5’xxxxxxxxxxxxxxx-2-xx)xxxxxxx-4-xxxxxxxxxxx, fluxapyroxadu,

—

stanovisko xx xxx 8. xxxxxx 2018 ohledně N-(hydroxymethyl)akrylamidu, xxxxxxxxxxxxxxxxxx, [NMA],

—

stanovisko xx xxx 15. října 2018 xxxxxxx 5-xxxxx-1,3-xxxxxxxx-X-[2-(4-xxxxxxxxxxxx-2-xx)xxxxx]-1X-xxxxxxx-4-xxxxxxxxxxx, 2’-[(XX)-1,3-xxxxxxxxxxxxx]-5-xxxxx-1,3-xxxxxxxxxxxxxxx-4-xxxxxxxxxxxxx, xxxxxxxxxx,

—

xxxxxxxxxx xx xxx 30. listopadu 2018 xxxxxxx xxxxxxxxxxxxx (XXX), isopropyl [(2S)-3-methyl-1-{[1-(4-methylfenyl)ethyl]amino}-1-oxobutan-2-yl]karbamátu,

—

stanovisko xx xxx 30. xxxxxxxxx 2018 xxxxxxx xxxxxxxxxxx (XXX), X-xxxxx-4,5-xxxxxxxx-2(xxxxxxxxxxxxxx)xxxxxxx-3-xxxxxxxxxxx,

—

xxxxxxxxxx xx xxx 9. xxxxxx 2018 xxxxxxx xxxxxxx, xxxxxxx [xxxx xxxxxxxx xx studena xx semen rostliny Xxxxxxxxxxx xxxxxx bez xxxxxxxx, xxxxxxxxxxx xxxxxxxxxxxxxx xxxxxx uhličitým],

—

stanovisko xx xxx 8. června 2018 ohledně xxxxxxxx xxxxxxx …%[C> 70 %],

—

xxxxxxxxxx z 9. xxxxxx 2018 xxxxxxx xxxxxxxxxxxxxxxxxxxxxxxxxxxx, [D4],

—

stanovisko xx xxx 30. xxxxxxxxx 2018 xxxxxxx pirimifos-methylu (XXX), X-[2-(xxxxxxxxxxx)-6-xxxxxxxxxxxxxxx-4-xx]-X,X-xxxxxxxx-xxxxxxxxxxxxx,

—

xxxxxxxxxx xx 30. xxxxxxxxx 2018 xxxxxxx fosfinu,

—

stanovisko xx xxx 14. xxxx 2018 ohledně dichlordioktylstannanu,

—

stanovisko xx xxx 30. xxxxxxxxx 2018 ohledně 2-xxxxxxxxxx-10-xxxxx-4,4-xxxxxxx-7-xxx-8-xxx-3,5-xxxxxx-4-xxxxxxxxxxx-xxxxxxxxx, [XXXX],

—

xxxxxxxxxx ze xxx 30. listopadu 2018 xxxxxxx olova,

—

stanovisko xx xxx 14. xxxx 2018 xxxxxxx 2-xxxxxxxxxxxxxx, xxxxxxxxxxxxx-xxxxxxxxx-xxxxxx,

—

xxxxxxxxxx ze xxx 30. xxxxxxxxx 2018 xxxxxxx x-xxx(2,3-xxxxxxxxxxxx)xxxxxxx, xxxxxxxxxx-xxxxxxxxxx-xxxxxx,

—

xxxxxxxxxx xx dne 14. září 2018 xxxxxxx xxxxxxxxxx-xxxxxxx (XXX), xxxxxx 2-[X-(4-xxxxxxx-6-xxxxxx-1,3,5-xxxxxxx-2-xx)-X-xxxxxxxxxxxxxxxxxxxxxxxx]xxxxxxxx,

—

xxxxxxxxxx xx xxx 8. xxxxxx 2018 ohledně azoxystrobinu (XXX), methyl (X)-2-{2-[6-(2-xxxxxxxxxxx)xxxxxxxxx-4-xxxxx]xxxxx}-3-xxxxxxxxxxxxxxx,

—

xxxxxxxxxx xx xxx 9. xxxxxx 2018 xxxxxxx xxxxxxxxxxxx (XXX), (XX)-2-xxxxxx-2,3-xxxxxxx-3,3-xxxxxxxxxxxxxxxxxx-5-xx-xxxxxxxxxxxxxxx,

—

xxxxxxxxxx xx dne 30. xxxxxxxxx 2018 xxxxxxx 2,4-xxxxxxxxxxxxx,

—

xxxxxxxxxx ze xxx 14. xxxx 2018 xxxxxxx xxxxxxxxxx (ISO), 2-[4-(xxxxxxxxxxxxxx)-2-xxxxxxxxxxxx]-1,3-xxxxxxxxxxxxxxx,

—

xxxxxxxxxx ze xxx 30. xxxxxxxxx 2018 xxxxxxx okthilinonu (ISO), 2-xxxxx-2X-xxxxxxxxxx-3-xxx, [OIT],

—

stanovisko xx xxx 14. září 2018 xxxxxxx xxxxxxxxxx (XXX), 3-hydroxy-5-methylisoxazolu,

—

stanovisko xx xxx 30. xxxxxxxxx 2018 xxxxxxx hexythiazoxu (XXX), xxxxx-5-(4-xxxxxxxxxx)-X-xxxxxxxxxx-4-xxxxxx-2-xxx-3-xxxxxxxxxxx-xxxxxxxxxxx,

—

xxxxxxxxxx xx xxx 9. xxxxxx 2018 xxxxxxx pymetrozinu (XXX), (E)-4,5-dihydro-6-methyl-4-(3-pyridylmethylen-amino)-1,2,4-triazin-3(2H)-onu,

—

stanovisko xx xxx 9. xxxxxx 2018 xxxxxxx xxxxxxxxxxxx (XXX), reakční xxxxx: [2,4-xxxxx-(2-xxxxxx-1-xx)xxxxxxxxxxxx-3-xx]xxxxxx(1X)-xxx-xxxxxxxxxxxxxx, [2,4-dioxo-(2-propyn-1-yl)imidazolidin-3-yl]methyl(1R)-trans-chrysanthematu,

—

stanovisko ze xxx 14. září 2018 butanon-oximu, xxxxxxxxxxxxxxxxxxx, xxxxxxxxxxxxxxxxxxxxx,

—

xxxxxxxxxx ze xxx 8. xxxxxx 2018 xxxxxxx bis(α,α-dimethylbenzyl)-peroxidu,

—

stanovisko xx xxx 9. xxxxxx 2018 xxxxxxx xxxxxxxxxxxx xxxxxxxxxxxxxxx,

—

xxxxxxxxxx xx dne 30. xxxxxxxxx 2018 xxxxxxx xxxxx 2-(1-(xxxxxxxxxxxxxxxxxxxxxxxx) xxxxxxxxx)xxxxxxxx, hexyl 2-[4-(xxxxxxxxxxx)-2-xxxxxxxxxxxxxx]xxxxxxxx.

(3)

Xxxxx xxx x xxxxx xxxxx (xxxxx CAS 7439–92–1 a xxxxxxxx xxxxx 082–013–00–1 (xxxxx x xxxxxx; [průměr xxxxxx < 1 xx];) x 082–014–00–7 (xxxxxxxx xxxxx; [xxxxxx xxxxxx ≥ 1 xx];)), RAC xx xxxx xxxxxxxxxx ze xxx 30. listopadu 2018 xxxxxx použít xxxxxxx environmentální klasifikaci xx celistvou x xxxxxxxxx formu. Xxxxx xxxxxxxx x xxxxx xxxxxxxxx xxxxxxxxxxx xxxxxxxx xxxxx, xxxxxx struktuře xxxxx, ke specifické xxxxxxx výrobě xxxxxx x vzhledem x xxxxx environmentální klasifikaci x xxxxxxxxxx a xxxxxxxxxx forem xxxxxx xxxx x xxxxxxxxxxxx xxxxxxxxx x xxxxxxx XX musí XXX xxxxxxx xxxxx xxxxxxxxx xxxx, xxx xx xxx xx xxxxxxxxx x práškovou formu xxxxx xxxxxxx stejná xxxxxxxxxxxxxxx xxxxxxxxxxx. Kromě xxxx byly předloženy xxxx xxxxxxx xxxxxxxx, x xxxxx xxxxxxx, xx xxxxxxxxxxxxxxx klasifikace xxx xxxxxxxxx xxxxx, xxx xx doporučilo xxxxxxxxxx xxxxxx XXX, xxxxxx být xxxxxx. Xxxxxxxxxxxxxxx xxxxxxxxxxx xxx xxxxxxxxx xxxxx xxxxx xxxxxx xxxxxxxx xx xxxxxxx XX nařízení (XX) č. 1272/2008, xxxxx XXX nebude xxx xxxxxxx předložit xxxxxxxxxx xxxxxxxxxx.

(4)

Xxxxx xxx x xxxxx 2-butoxyethanol, xxxxxxxxxxxxx-xxxxxxxxx-xxxxx, (xxxxx CAS 111-76-2), pro xxxxx xxxxxxxxxxxxx „akutní xxxxxxxx (xxxxxxxxx)“ xxxx předloženy xxxx xxxxxxx xxxxxxxx, xx kterých xxxxxxx, xx xxxxxxxxxxx pro xxxx třídu xxxxxxxxxxxxx xxxxxxxxxxxx ve xxxxxxxxxx xxxxxx XXX, jež xx zakládá xx xxxxxxxx xxxxxxx, xxxxxx xxx xxxxxx. Xxxx xxxxx xxxxxxxxxxxxx xx xxxxx xxxxxx být x xxxxxxx XX xxxxxxxx (ES) č. 1272/2008 xxxxxxx, dokud XXX xxxxxx mít xxxxxxx předložit x xxxxx xxxxx xxxxxxxxxx xxxxxxxxxx xxxxxxxxxx; xxxxxxx xxxxxxx xxxxx xxxxxxxxxxxxx, x xxxxxxx xxxxxxxxx xxxxxxxxxx výboru XXX, xx xxxxxxxx xxx xxxx.

(5)

Xxxxxxxx (ES) x. 1272/2008 by xxxxx xxxx xxx xxxxxxxxxxxxx xxxxxxxx xxxxxxx.

(6)

Xxxxxxxxxx nových xxxx aktualizovaných xxxxxxxxxxxxxxx xxxxxxxxxxx by nemělo xxx, s výhradou xxxxxxxxxxx regulatorních požadavků, xxxxxxxxxx xxxxx, xxxxxxx xxxxxxxxxx potřebují xxxxxxx xxxx na xx, xxx přizpůsobili xxxxxxxxxx x balení xxxxx x xxxxx novým xxxx xxxxxxxxxxx klasifikacím x prodali xxxxxxxxx xxxxxx. Tato xxxx xx xxxxxx nezbytná x tomu, xxx xxxxxxxxxx měli xxxxxxxx xxxx xxxxxxxx xxxxxxxx xxxxx x zajištění xxxxxxxx xxxxxxxxxx dalších xxxxxxxx xxxxxxxxx, xxxxx xxxxxxxx x důsledku xxxx xxxxxxxxxxx podle xxxxxx xxxxxxxx. Xxxx xxxxxxxxx xxxxx zahrnovat xxxxxxxxx xxxxxxxxx v xx. 22 odst. 1 xxxx. x) xxxxxxxx Xxxxxxxxxx xxxxxxxxxx x Xxxx (ES) x. 1907/2006&xxxx;(3) xxxx xxxxxxxxx xxxxxxxxx x xxxxxx 50 xxxxxxxx Xxxxxxxxxx xxxxxxxxxx x Xxxx (EU) č. 528/2012&xxxx;(4).

(7)

Xxxxxxxxxxx xx však xxxx xxx xxxxxxxx, xxx xxxxx nová xxxxxxxxxx xxxxxxxx se xxxxxxxxxxx, xxxxxxxxxx x xxxxxx xxxxxxxxxx xxxxxxxxxx xxxxx xxxx použitelnosti xxxxxx xxxxxxxx. Xx xx v xxxxxxx x xxxxxxxxx xxxxx xx. 61 xxxx. 2 xxxxxxxx (XX) x. 1272/2008,

PŘIJALA XXXX XXXXXXXX:

Článek 1

Změny nařízení (XX) x. 1272/2008

Xxxxxxx 3 v xxxxx 3 xxxxxxx XX xxxxxxxx (XX) č. 1272/2008 xx xxxx x xxxxxxx x xxxxxxxx tohoto nařízení.

Xxxxxx 2

Xxxxx x xxxxxxxx x xxxxxxxxxxxx

Xxxx xxxxxxxx vstupuje v xxxxxxxx dvacátým xxxx xx xxxxxxxxx v Xxxxxxx věstníku Xxxxxxxx xxxx.

Xxxxxxx se xxx xxx 1. xxxxxx 2022.

Xxxxxxxx od xxxxxxx xxxxxxxxxxx xxxxxx xxxxxx xxxxx xxx látky x xxxxx xxxxxxxxxxxxx, xxxxxxxxxx a xxxxxx x xxxxxxx s xxxxxxxxx (XX) x. 1272/2008 xx xxxxx xxxxxx xxxxxxxx xxxxx xxxxx xxxx 1. xxxxxx 2022.

Xxxx nařízení xx xxxxxxx x xxxxx xxxxxxx x xxxxx xxxxxxxxxx xx všech xxxxxxxxx xxxxxxx.

X Bruselu xxx 19. xxxxxx 2020.

Xx Xxxxxx

Xxxxxx XXX XXX XXXXX

xxxxxxxxxxx

(1)&xxxx;&xxxx;xxxxXx. xxxx. X 353, 31.12.2008, x. 1.

(2)  Stanoviska xxxx xxxxxxxx xx xxxx xxxxxxxxxxx xxxxxxx: xxxxx://xxxx.xxxxxx.xx/xxxxxxxx-xx-xxx-xxxxxxxxxx-xxxxx-xxxxxxx/-/xxxxxxx/xxxx/-/xxXxxxxx/-/xxxXxxxxx/-/xxx_xxxxxxxXxxx/-/xxx_xxxxxxxXx/-/xxx_xxxxxx_xxxxxx/Xxxxxxx+Xxxxxxx/xxx_xxxxxxxxxXxxx/-/xxx_xxxxxxxxxXx/-/xxx_xxxxxxxx_xxxxxxxxxxXxxx/-/xxx_xxxxxxxx_xxxxxxxxxxXx/-/xxx_xxxxxxxx_xxxxxxxxXxxx/-/xxx_xxxxxxxx_xxxxxxxxXx/-/xxx_xxxxxxxx_xxxxxx/-/xxx_xxxxxxxxx/-/xxx_xxxxxxxxxxXxxx/-/xxx_xxxxxxxxxxXx/-/xxx_xxxxxxxxxx_xxxxxxxxx/-/

(3)&xxxx;&xxxx;Xxxxxxxx Xxxxxxxxxx xxxxxxxxxx a Xxxx (XX) x. 1907/2006 xx xxx 18. prosince 2006

x xxxxxxxxxx, xxxxxxxxx, povolování x xxxxxxxxx xxxxxxxxxx xxxxx, x xxxxxxx Xxxxxxxx xxxxxxxx xxx xxxxxxxx xxxxx, x xxxxx směrnice 1999/45/ES x x xxxxxxx xxxxxxxx Rady (EHS) x. 793/93, xxxxxxxx Xxxxxx (XX) x. 1488/94, xxxxxxxx Xxxx 76/769/XXX x xxxxxxx Xxxxxx 91/155/XXX, 93/67/XXX, 93/105/XX x 2000/21/ES (Xx. věst. X 396, 30.12.2006, s. 1).

(4)&xxxx;&xxxx;Xxxxxxxx Xxxxxxxxxx xxxxxxxxxx x Xxxx (XX) x. 528/2012 xx xxx 22. xxxxxx 2012

x xxxxxxxx biocidních xxxxxxxxx na xxx x jejich xxxxxxxxx

(Xx. xxxx. X 167, 27.6.2012, x. 1).

PŘÍLOHA

V příloze XX xxxxxxxx (XX) č. 1272/2008 xx xxxxxxx 3 x xxxxx 3 xxxx xxxxx:

1)

Xxxxxxxx xx xxxx xxxxxxx:

Xxxxxxxx xxxxx

Xxxxxxxx xxxxx

Xxxxx XX

Xxxxx XXX

Xxxxxxxxxxx

Xxxxxxxx

Xxxxxxxxxx xxxxxxx. xxxxxx, xxxxxxxxxxxxx xxxxxxx x XXX

Xxxxxxxx

Xxxx xxxx a xxxxxxxxx xxxxxxxxxxxxx

Xxxx xxxxxxxxxxxx xxx o nebezpečnosti

Kódy xxxxxxxxxxx symbolů x xxxxxxxxxx xxxx

Xxxx xxxxxxxxxxxx xxx o xxxxxxxxxxxxx

Xxxx xxxxx. standardních xxx x xxxxxxxxxxxxx

„007-030-00-3

xxxxxxxx dusičná …% [X ≤ 70 %]

231-714-2

7697-37-2.

Ox. Xxx. 3

Xxxxx Xxx. 3

Skin Xxxx. 1 X

X272

X331

X314

XXX03

XXX06

XXX05

Xxx

X272

X331

X314

XXX071

Xx. Xxx. 3; H272: X ≥ 65 %

xxxxxxxxx: XXX = 2,65 xx/x (xxxx)

Xxxx Xxxx. 1 X; X314: X ≥ 20 %

Xxxx Corr. 1X; H314: 5 % ≤ X &xx; 20 %

B“

„014-048-00-5

vlákna x xxxxxxx křemíku (x xxxxxxx &xx; 3 μx, xxxxx &xx; 5 μm x x poměrem xxxxx ≥ 3:1)

206-991-8

409-21-2

308076-74-6

Xxxx. 1X

X350x

XXX08

Xxx

X350x“

„014-049-00-0

xxxxxxxxxxxxxxxxxxxx; xxxxxxxxxx(xxxxx)xxxxx

220-449-8

2768-02-7

Xxxx Sens. 1X

X317

XXX07

Xxx

X317“

„014-050-00-6

xxxx(2-xxxxxxxxxxxxx)xxxxxxxxxx;

6-(2-xxxxxxxxxxxxx)-6-xxxxx-2,5,7,10-xxxxxxxx-6-xxxxxxxxxxx

213-934-0

1067-53-4

Xxxx. 1B

H360FD

GHS08

Dgr

H360FD“

„016-098-00-3

dimethyl-disulfid

210-871-0

624-92-0

Flam. Xxx. 2

Xxxxx Xxx. 3

Xxxxx Xxx. 3

XXXX XX 3

XXXX XX 1

Eye Xxxxx. 2

Xxxx Xxxx. 1

Xxxxxxx Acute 1

Aquatic Xxxxxxx 1

X225

X331

X301

X336

X370 (horní xxxxxxx xxxxx, xxxxxxxxx)

X319

X317

X400

X410

XXX02

XXX06

XXX08

XXX09

Xxx

X225

X331

X301

X336

X370 (xxxxx xxxxxxx xxxxx, xxxxxxxxx)

X319

X317

X410

xxxxxxxxx: ATE = 5 mg/l (xxxx)

xxxxxx: XXX = 190 xx/xx XX

X = 1

X = 10“

„029-024-00-X

granulovaná xxx;

[xxxxx xxxxxx: xx 0,9 xx x xx 6,0 xx; xxxxx xxxxxx: od 0,494 do 0,949 xx]

231-159-6

7440-50-8

Xxxxxxx Chronic 2

X411

XXX09

X411“

„029-025-00-5

xxx(X-xxxxxxx-X-xxxxxxxxxxxxxxxxxxxxxxxx-X,X’)xxx;

xxx(X-xxxxxxxxxx-xxxxxxxxx-xxxxx)-xxx;

[Xx-XXX]

239-703-4

312600-89-8

15627-09-5

Xxxx. Xxx. 1

Xxxxx Tox. 4

XXXX XX 2

Xxx Xxx. 1

Aquatic Xxxxx 1

Xxxxxxx Xxxxxxx 1

X228

X302

X373 (xxxxx)

X318

X400

X410

XXX02

XXX07

XXX08

XXX05

XXX09

Xxx

X228

X302

X373 (xxxxx)

X318

X410

xxxxxx: XXX = 360 xx/xx XX

X = 1

X = 1“

„050-031-00-9

xxxxxxxxxx-xxxxxxxx; [1]

stannan, xxxxxxx-, xxx(xxxx xxxxxxx) xxxxxxxx [2]

222-883-3 [1] 293-901-5 [2]

3648-18-8 [1] 91648-39-4 [2]

Xxxx. 1X

XXXX XX 1

X360X

X372 (imunitní xxxxxx)

XXX08

Xxx

X360X

X372 (xxxxxxxx xxxxxx)“

„601-092-00-0

xxxxxxx[xxx,x]xxxxxxx;

xxxxxxx[x,x]xxxxx

205-886-4

191-30-0

Xxxx. 1X

Xxxx. 2

H350

H341

GHS08

Dgr

H350

H341

Carc. 1X; X350: X ≥ 0,001 %“

„603-237-00-3

xxxxxxxxx (ISO);

(1RS,2SR,5RS;1RS,2SR,5SR)-2-(4-chlorbenzyl)-5-isopropyl-1-(1H-1,2,4-triazol-1-ylmethyl)cyklopentanol

–

125225-28-7

115850-69-6

115937-89-8

Repr. 1X

Xxxxx Xxx. 4

XXXX XX 2

Xxxxxxx Chronic 1

X360X

X302

X373 (xxx, xxxx, xxxxx)

X410

XXX08

XXX07

XXX09

Xxx

X360X

X302

X373 (xxx, xxxx, xxxxx)

X410

xxxxxx: ATE = 500 xx/xx XX

X = 100“

„603-238-00-9

xxx(2-(2-xxxxxxxxxxxxx)xxxxx)-xxxxx; xxxxxxxxx

205-594-7

143-24-8

Xxxx. 1X

X360XX

XXX08

Xxx

X360XX“

„603-239-00-4

xxxxxxxxxxxxx (XXX);

(2XX,3XX)-1-(4-xxxxxxxxxx)-4,4-xxxxxxxx-2-(1X-1,2,4-xxxxxxx-1-xx)xxxxxx-3-xx

–

76738-62-0

Xxxx. 2

Xxxxx Xxx. 4

Xxxxx Xxx. 4

Xxx Xxxxx. 2

Xxxxxxx Xxxxx 1

Aquatic Chronic 1

X361x

X332

X302

X319

X400

X410

XXX08

XXX07

XXX09

Xxx

X361x

X332

X302

X319

X410

xxxxxxxxx: XXX = 3,13 xx/x (xxxxx xxxx xxxx)

xxxxxx: ATE = 490 xx/xx XX

X = 10

M = 10“

„603-240-00-X

2,2-bis(brommethyl)propan-1,3-diol

221-967-7

3296-90-0

Carc. 1X

Xxxx. 1X

X350

X340

XXX08

Xxx

X350

X340“

„603-241-00-5

xxxxxxxx;

(2X)-3,7-xxxxxxxxxxxx-2,6-xxxx-1-xx

203-377-1

106-24-1

Xxxx Xxxx. 1

X317

XXX07

Xxx

X317“

„605-041-00-3

2-(4-xxxx-xxxxxxxxxxx)xxxxxxxx

201-289-8

80-54-6

Xxxx. 1X

X360Xx

XXX08

Xxx

X360Xx“

„607-738-00-8

XXXX-xxxxxxxxx (XXX);

X-xxxxx (4-xxxxx-2-xxxxxxxxxxxx)xxxxxxxxxxxx; X-xxxxx 4-xxxxx-x-xxxxxxxxxxxxxxxxxx

246-831-4

25319-90-8

Xxxxx Tox. 4

XXXX XX. 2

Aquatic Xxxxx 1 Xxxxxxx Xxxxxxx 1

H302

H373 (xxxxx)

X400

X410

XXX07

XXX08

XXX09

Xxx

X302

X373 (xxxxx)

X410

xxxxxx: XXX = 450 xx/xx TH

M = 10

M = 10“

„607-740-00-9

xxxxxxxxxx-xxxxxx

248-523-5

27554-26-3

Xxxx. 1B

H360FD

GHS08

Dgr

H360FD“

„607-741-00-4

4-{[(6-chlorpyridin-3-yl)methyl](2,2-difluorethyl)amino}furan-2(5H)-on; flupyradifuron

–

951659-40-8

Acute Xxx. 4

XXXX XX 2

Xxxxxxx Xxxxx 1

Aquatic Xxxxxxx 1

X302

X373 (xxxxxxxxx)

X400

X410

XXX07

XXX08

XXX09

Xxx

X302

X373 (xxxxxxxxx)

X410

xxxxxx: ATE = 500 xx/xx TH

M = 10

X = 10“

„607-742-00-X

xxxxxxxxxxxxx-xxxxxx (XXX);

xxxxxx-4-[(4,5-xxxxxxx-3-xxxxxxx-4-xxxxxx-5-xxx-1X-1,2,4-xxxxxxx-1-xx)xxxxxxxxxxxxxxxxx]-5-xxxxxxxxxxxxx-3-xxxxxxxxxx

–

317815-83-1

Xxxxxxx Acute 1

Xxxxxxx Xxxxxxx 1

H400

H410

GHS09

Wng

H410

M = 1000

X = 1000“

„607-743-00-5

X-(+)-xxxxxx xxxxxxxx;

(2 X)-2-xxxxxxxxxxxxxxxx xxxxxxxx

201-196-2

79-33-4

Xxxx Xxxx. 1X

Xxx Xxx. 1

X314

X318

XXX05

Xxx

X314

XXX071“

„607-744-00-0

2-xxxxxxxxxxxxxxxxxxx

221-499-3

3121-61-7

Xxxx. Liq. 3

Xxxx. 2

Xxxx. 1X

Xxxxx Xxx. 3

Xxxxx Xxx. 4

Xxxx Corr. 1X

Xxx Xxx. 1

Xxxx Sens. 1

X226

X341

X360XX

X331

X302

X314

X318

X317

XXX02

XXX05

XXX06

XXX08

Xxx

X226

X341

X360XX

X331

X302

X314

X317

XXX071

xxxxxxxxx: XXX = 2,7 xx/x (xxxx)

xxxxxx: XXX = 404 xx/xx XX“

„607-745-00-6

xxxxxxxxxx xxxxxxxx …%

206-058-5

298-12-4

Xxx Xxx. 1

Skin Xxxx. 1X

X318

X317

XXX05

XXX07

Xxx

X318

X317

X“

„607-746-00-1

xxxxxxx-X-(xxxxxxxxxxxxx)xxxxxxxx;

[xxxxxxxxxxx xxxxxxxx x xxxxxxx-X-(xxxxxxxxxxxxx)xxxxxxxxx]

274-357-8

70161-44-3

Xxxx. 1B

Muta. 2

Xxxxx Tox. 4

Xxxxx Xxx. 4

XXXX XX 3

Xxxx Xxxxx. 2

Xxx Xxxxx. 2

Skin Xxxx. 1

X350

X341

X332

X302

X335

X315

X319

X317

XXX08

XXX07

Xxx

X350

X341

X332

X302

X335

X315

X319

X317

xxxxxxxxx: ATE = 3 xx/x (xxxxx xxxx xxxx)

xxxxxx: ATE = 1&xxxx;100 xx/xx XX

8

9“

„611-181-00-6

(xxxxx-XXX-xxxxx)xxxxxxxxxx xxxxxxxx;

xxxxxxxxxxxxxxxxxxxxxxx-1-xxxx, draselná xxx;

[X-XXX]

–

66603-10-9

Xxxx. Xxx. 1

Xxxxx Xxx. 3

XXXX XX 2

Xxxx Xxxxx. 2

Eye Xxx. 1

Xxxxxxx Chronic 2

X228

X301

X373 (játra)

H315

H318

H411

GHS02

GHS06

GHS08

GHS05

GHS09

Dgr

H228

H301

H373 (játra)

H315

H318

H411

orální: XXX = 136 xx/xx TH“

„612-294-00-3

mecetroniumetilsulfát;

N-ethyl-N,N-dimethylhexadekan-1-aminium-ethyl-sulfát;

mecetronium-ethyl-sulfát;

[MES]

221-106-5

3006-10-8

Skin Corr. 1

Xxx Xxx. 1

Xxxxxxx Xxxxx 1

Aquatic Xxxxxxx 1

X314

X318

X400

X410

XXX05

XXX09

Xxx

X314

X410

XXX071

X = 100

X = 1 000 “

„613-331-00-6

(2XX)-2-[4-(4-xxxxxxxxxxx)-2-(xxxxxxxxxxxxxx)xxxxx]-1-(1X-1,2,4-xxxxxxx-1-xx)xxxxxx-2-xx;

xxxxxxxxxxxxxxxxxx

–

1417782-03-6

Xxxx Xxxx. 1

Xxxxxxx Acute 1

Xxxxxxx Xxxxxxx 1

X317

X400

X410

XXX07

XXX09

Xxx

X317

X410

X = 1

X = 1“

„613-332-00-1

xxxxxxxxxxxxxxx (XXX);

1-(4-{4-[5-(2,6-xxxxxxxxxxxx)-4,5-xxxxxxx-1,2-xxxxxx-3-xx]-1,3-xxxxxxx-2-xx}xxxxxxxxx-1-xx)-2-[5-xxxxxx-3-(xxxxxxxxxxxxxx)-1X-xxxxxxx-1-xx]xxxxxxx

–

1003318-67-9

Xxxxxxx Xxxxxxx 1

X410

XXX09

Xxx

X410

X = 1“

„613-333-00-7

pyrithion-zinek; (X-4)-xxx[1-(xxxxxxx-.xxxxx.X)xxxxxxx-2(1X)-xxxxxxxx-.xxxxx.X]xxxxx

236-671-3

13463-41-7

Xxxx. 1X

Xxxxx Tox. 2

Xxxxx Xxx. 3

STOT XX 1

Xxx Dam. 1

Xxxxxxx Acute 1

Aquatic Xxxxxxx 1

H360D

H330

H301

H372

H318

H400

H410

GHS08

GHS06

GHS05

GHS09

Dgr

H360D

H330

H301

H372

H318

H410

inhalační: ATE = 0,14 xx/x (xxxxx nebo xxxx)

xxxxxx: XXX = 221 xx/xx XX

X = 1&xxxx;000

X = 10“

„613-334-00-2

xxxxxxxxxxxxxx (XXX);

3-xxxxx-4-(xxxxxxxxxxx)-1-[3-(xxxxxxxxxxxxxx)xxxxx]xxxxxxxxxx-2-xx

262-661-3

61213-25-0

Xxxx. 1X

Xxxxx Xxx. 4

Xxxx Xxxx. 1

Xxxxxxx Xxxxx 1

Aquatic Chronic 1

X360XX

X302

X317

X400

X410

XXX08

XXX07

XXX09

Xxx

X360XX

X302

X317

X410

xxxxxx: XXX = 500 mg/kg XX

X = 100

X = 100“

„613-335-00-8

4,5-xxxxxxx-2-xxxxx-2X-xxxxxxxxxx-3-xx; [DCOIT]

264-843-8

64359-81-5

Acute Xxx. 2

Xxxxx Xxx. 4

Xxxx Xxxx. 1

Xxx Xxx. 1

Xxxx Xxxx. 1 X

Xxxxxxx Acute 1

Xxxxxxx Xxxxxxx 1

X330

X302

X314

X318

X317

X400

X410

XXX06

XXX05

XXX09

Xxx

X330

X302

X314

X317

X410

XXX071

xxxxxxxxx: XXX = 0,16 mg/l (xxxxx nebo xxxx)

xxxxxx: XXX = 567 xx/xx XX

Xxxx Xxxxx. 2; H315: 0,025 % ≤ X &xx; 5 %

Xxx Xxxxx. 2; H319: 0,025 % ≤ X &xx; 3 %

Xxxx Xxxx. 1 X; X317: X ≥ 0,0015 %

X = 100

M = 100“

„613-336-00-3

2-xxxxxx-1,2-xxxxxxxxxxxx-3(2X)-xx;

[XXXX]

–

2527-66-4

Xxxxx Xxx. 4

Xxxxx Xxx. 3

Xxxx Corr. 1X

Xxx Xxx. 1

Xxxx Xxxx. 1 A

Aquatic Xxxxx 1

Xxxxxxx Xxxxxxx 2

X312

X301

X314

X318

X317

X400

X411

XXX06

XXX05

XXX09

Xxx

X312

X301

X314

X317

X410

XXX071

xxxxxxxx: ATE = 1&xxxx;100 xx/xx XX

xxxxxx: XXX = 175 xx/xx XX

Xxxx Sens. 1 X; X317: X ≥ 0,0015 %

X = 1“

„616-228-00-4

3-(xxxxxxxxxxxxx)-1-xxxxxx-X-(3‘,4’,5’-xxxxxxxxxxxxxxx-2-xx)xxxxxxx-4-xxxxxxxxxx;

xxxxxxxxxxxx

–

907204-31-3

Xxxx.

Xxxxxxx Xxxxx 1

Aquatic Xxxxxxx 1

X362

X400

X410

XXX09

Xxx

X362

X410

X = 1

X = 1“

„616-230-00-5

X-(xxxxxxxxxxxxx)xxxxxxxxx; xxxxxxxxxxxxxxxxx; [XXX]

213-103-2

924-42-5

Xxxx. 1X

Xxxx. 1X

XXXX XX 1

X350

X340

X372 (xxxxxxxxx xxxxxxx systém)

GHS08

Dgr

H350

H340

H372 (periferní xxxxxxx xxxxxx)“

„616-231-00-0

5-xxxxx-1,3-xxxxxxxx-X-[2-(4-xxxxxxxxxxxx-2-xx)xxxxx]-1X-xxxxxxx-4-xxxxxxxxxx; 2’-[(XX)-1,3-xxxxxxxxxxxxx]-5-xxxxx-1,3-xxxxxxxxxxxxxxx-4-xxxxxxxxxxxx;

xxxxxxxxx

–

494793-67-8

Xxxx. 2

Xxxxxxx Xxxxx 1

Xxxxxxx Xxxxxxx 1

X351

X400

X410

XXX08

XXX09

Xxx

X351

X410

X = 1

X = 1“

„616-232-00-6

iprovalikarb (XXX);

xxxxxxxxx [(2X)-3-xxxxxx-1-{[1-(4-xxxxxxxxxxx)xxxxx]xxxxx}-1-xxxxxxxx-2-xx]xxxxxxxx

–

140923-17-7

Xxxx. 2

X351

XXX08

Xxx

X351“

„616-233-00-1

xxxxxxxxxx (XXX);

X-xxxxx-4,5-xxxxxxxx-2-(xxxxxxxxxxxxxx)xxxxxxx-3-xxxxxxxxxx

–

175217-20-6

XXXX RE 2

Xxxxxxx Xxxxxxx 2

X373

X411

XXX08

XXX09

Xxx

X373

X411“

„650-057-00-6

Xxxxxxx, xxxxxxx [xxxx xxxxxxxx za xxxxxxx xx xxxxx xxxxxxxx Xxxxxxxxxxx xxxxxx xxx xxxxxxxx, xxxxxxxxxxx xxxxxxxxxxxxxx xxxxxx xxxxxxxxx]

283-644-7

84696-25-3

Xxxxxxx Xxxxxxx 3

X412

X412“

2)

xxxxxxx odpovídající xxxxxxxxx xxxxxx 007-004-00-1; 014-018-00-1; 015-134-00-5; 015-181-00-1; 050-021-00-4; 050-027-00-7; 082-013-00-1; 603-014-00-0; 603-065-00-9; 605-019-00-3; 607-177-00-9; 607-256-00-8; 607-314-00-2; 609-041-00-4; 609-064-00-X; 613-112-00-5; 613-115-00-1; 613-125-00-6; 613-202-00-4; 613-259-00-5; 616–014–00–0 x 617–006–00-X se xxxxxxxxx xxxxxx xxxxxxxxx:

Xxxxxxxx xxxxx

Xxxxxxxx xxxxx

Xxxxx XX

Xxxxx XXX

Xxxxxxxxxxx

Xxxxxxxx

Xxxxxxxxxx xxxxxxx. limity, multiplikační xxxxxxx x ATE

Poznámky

Kódy xxxx x xxxxxxxxx xxxxxxxxxxxxx

Xxxx standardních xxx x xxxxxxxxxxxxx

Xxxx výstražných xxxxxxx x signálních xxxx

Xxxx xxxxxxxxxxxx xxx x nebezpečnosti

Kódy xxxxx. xxxxxxxxxxxx vět x xxxxxxxxxxxxx

„007-004-00-1

xxxxxxxx xxxxxxx …% [X > 70 %]

231-714-2

7697-37-2

Xx. Xxx. 2

Acute Xxx. 1

Skin Xxxx. 1 X

X272

X330

X314

XXX03

XXX06

XXX05

Xxx

X272

X330

X314

XXX071

Xx. Xxx. 2; H272: C ≥ 99 %

Xx. Xxx. 3; X272: 70 % ≤ X < 99 %

X“

„014-018-00-1

xxxxxxxxxxxxxxxxxxxxxxxxxxx;

[X4]

209-136-7

556-67-2

Xxxx. 2

Xxxxxxx Chronic 1

X361x ***

X410

XXX08

XXX09

Xxx

X361x ***

X410

X = 10“

„015-134-00-5

xxxxxxxxx-xxxxxx (XXX);

X-[2-(xxxxxxxxxxx)-6-xxxxxxxxxxxxxxx-4-xx]-X,X-xxxxxxxx-xxxxxxxxxxxxx

249-528-5

29232-93-7

Xxxxx Xxx. 4

XXXX XX 1

Xxxxxxx Xxxxx 1

Xxxxxxx Xxxxxxx 1

X302

X372 (xxxxxxx xxxxxx)

X400

X410

XXX07

XXX08

XXX09

Xxx

X302

X372 (xxxxxxx xxxxxx)

X410

xxxxxx: XXX = 1&xxxx;414 xx/xx XX

X = 1&xxxx;000

X = 1&xxxx;000 “

„015-181-00-1

xxxxxx

232-260-8

7803-51-2

Xxxx. Xxx 1

Press. Xxx

Xxxxx Tox. 1

Xxxx Xxxx. 1X

Xxxxxxx Xxxxx 1

X220

X330

X314

X400

XXX02

XXX04

XXX06

XXX05

XXX09

Xxx

X220

X330

X314

X400

xxxxxxxxx:

XXX = 10 xxxX (plyny)

U“

„050-021-00-4

dichlordioktylstannan

222-583-2

3542-36-7

Repr. 1X

Xxxxx Xxx. 2

STOT RE 1

Xxxxxxx Chronic 3

X360X

X330

X372 **

X412

XXX08

XXX06

Xxx

X360X

X330

X372 **

H412

Repr. 1X; X360 X: X ≥ 0,03 %

xxxxxxxxx: XXX = 0.098 xx/X (prach xxxx xxxx)“

„050-027-00-7

2-xxxxxxxxxx 10-xxxxx-4,4-xxxxxxx-7-xxx-8-xxx-3,5-xxxxxx-4-xxxxxxxxxxxxxxxxxxx; [DOTE]

239-622-4

15571-58-1

Repr. 1X

XXXX XX 1

Aquatic Xxxxx 1

Aquatic Chronic 1

X360X

X372 (imunitní systém)

H400

H410

GHS08

GHS09

Dgr

H360D

H372 (xxxxxxxx xxxxxx)

X410“

„082-013-00-1

xxxxxxx xxxxxx; [xxxxxx částic &xx; 1 mm]

231-100-4

7439-92-1

Repr. 1 X

Xxxx.

Xxxxxxx Acute 1

Xxxxxxx Xxxxxxx 1

X360XX

X362

X400

X410

XXX08

XXX09

Xxx

X360XX H362

H410

Repr. 1 A; X360X: X ≥ 0,03 %

X = 1

X = 10“

„603-014-00-0

2-xxxxxxxxxxx-1-xx;

xxxxxxxxxxxxxxxxxxxxxxxxxxxx

203-905-0

111-76-2

Xxxxx Xxx. 4*

Xxxxx Xxx. 4

Xxxx Xxxxx. 2

Eye Xxxxx. 2

X332

X302

X315

X319

XXX07

Xxx

X332

X302

X315

X319

xxxxxx: ATE = 1&xxxx;200 mg/kg XX“

„603-065-00-9

x-xxx(2,3-xxxxxxxxxxxx)xxxxxx;

xxxxxxxxxxxxxxxxxxxxxxxxx

202-987-5

101-90-6

Xxxx. 1X

Xxxx. 2

Xxxxx Xxx. 3

Xxxxx Xxx. 4

Xxxx Xxxxx. 2

Xxx Xxxxx. 2

Xxxx Sens. 1

Aquatic Xxxxxxx 3

X350

X341

X311

X302

X315

X319

X317

X412

XXX08

XXX06

Xxx

X350

X341

X311

X302

X315

X319

X317

X412

xxxxxxxx: XXX = 300 mg/kg XX xxxxxx: ATE = 500 mg/kg XX“

„607-177-00-9

xxxxxxxxxx-xxxxxx (XXX);

xxxxxx-2-[X-(4-xxxxxxx-6-xxxxxx-1,3,5-xxxxxxx-2-xx)-X-xxxxxxxxxxxxxxxxxxxxxxxx]xxxxxxx

401-190-1

101200-48-0

XXXX XX 2

Xxxx Xxxx. 1

Xxxxxxx Xxxxx 1

Xxxxxxx Xxxxxxx 1

X373

X317

X400

X410

XXX08

XXX07

XXX09

Xxx

X373

X317

X410

X = 100

M = 100“

„607-256-00-8

xxxxxxxxxxxx (XXX);

xxxxxx (X)-2-{2-[6-(2-xxxxxxxxxxx)xxxxxxxxx-4-xxxxx]xxxxx}-3-xxxxxxxxxxxxxx

–

131860-33-8

Xxxxx Xxx. 3

Xxxxxxx Xxxxx 1

Aquatic Xxxxxxx 1

X331

X400

X410

XXX06

XXX09

Xxx

X331

X410

xxxxxxxxx:

XXX = 0,7 xx/x (prach xxxx xxxx)

X = 10

X = 10“

„607-314-00-2

xxxxxxxxxxx (ISO);

(RS)-2-ethoxy-2,3-dihydro-3,3-dimethylbenzofuran-5-yl xxxxxxxxxxxxxx

247-525-3

26225-79-6

Xxxxxxx Xxxxx 1

Aquatic Xxxxxxx 1

X400

X410

XXX09

Xxx

X410

X = 1

X = 1“

„609-041-00-4

2,4-xxxxxxxxxxxx

200-087-7

51-28-5

Xxxxx Xxx. 3 *

Xxxxx Xxx. 3

Xxxxx Xxx. 2

XXXX RE 1

Xxxxxxx Xxxxx 1

H331

H311

H300

H372

H400

GHS06

GHS08

GHS09

Dgr

H331

H311

H300

H372

H400

dermální: XXX = 300 xx/xx XX xxxxxx: XXX = 30 mg/kg XX“

„609-064-00-X

xxxxxxxxx (ISO);

2-[4-(methylsulfonyl)-2-nitrobenzoyl]-1,3-cyklohexandion

–

104206-82-8

Repr. 2

XXXX XX 2

Xxxxxxx Acute 1

Xxxxxxx Chronic 1

H361d

H373 (xxx, xxxxxxx systém)

H400

H410

GHS08

GHS09

Wng

H361d

H373 (xxx, xxxxxxx xxxxxx)

X410

X = 10

X = 10“

„613-112-00-5

xxxxxxxxxx (ISO);

2-oktyl-2H-isothiazol-3-on; [XXX]

247-761-7

26530-20-1

Xxxxx Xxx. 2

Acute Tox. 3

Xxxxx Tox. 3

Skin Xxxx. 1

Xxx Dam. 1

Xxxx Sens. 1 X

Xxxxxxx Acute 1 Xxxxxxx Xxxxxxx 1

H330

H311

H301

H314

H318

H317

H400

H410

GHS06

GHS05

GHS09

Dgr

H330

H311

H301

H314

H317

H410

EUH071

inhalační: XXX = 0,27 xx/x (prach xxxx xxxx)

xxxxxxxx: XXX = 311 xx/xx XX xxxxxx: ATE = 125 xx/xx XX

Xxxx Xxxx. 1 X; X317: X ≥ 0,0015 %

X = 100

X = 100“

„613-115-00-1

xxxxxxxxx (XXX);

3-xxxxxxx-5-xxxxxxxxxxxxxx

233-000-6

10004-44-1

Xxxx. 2

Acute Xxx. 4

Xxx Dam. 1

Skin Xxxx. 1

Aquatic Xxxxxxx 2

X361x

X302

X318

X317

X411

XXX08

XXX07

XXX05

XXX09

Xxx

X361x

X302

X318

X317

X411

xxxxxx: ATE = 1&xxxx;600 xx/xx XX“

„613-125-00-6

xxxxxxxxxxx (XXX);

xxxxx-5-(4-xxxxxxxxxx)-X-xxxxxxxxxx-4-xxxxxx-2-xxx-3-xxxxxxxxxxx-xxxxxxxxxx

–

78587-05-0

Xxxxxxx Acute 1

Aquatic Xxxxxxx 1

H400

H410

GHS09

Wng

H410

M = 1

X = 1“

„613-202-00-4

xxxxxxxxxx (XXX);

(X)-4,5-xxxxxxx-6-xxxxxx-4-(3-xxxxxxxxxxxxxxxxxxxxx)-1,2,4-xxxxxxx-3(2X)-xx

–

123312-89-0

Xxxx. 2

Xxxx. 2

Xxxxxxx Xxxxxxx 1

X351

X361xx

X410

XXX08

XXX09

Xxx

X351

X361xx

X410

X = 1“

„613-259-00-5

xxxxxxxxxxx (ISO);

reakční xxxx: [2,4-xxxxx-(2-xxxxxx-1-xx)xxxxxxxxxxxx-3-xx]xxxxxx(1X)-xxx-xxxxxxxxxxxxx; [2,4-dioxo-(2-propyn-1-yl)imidazolidin-3-yl]methyl(1R)-trans-chrysanthemát

428-790-6

72963-72-5

Carc. 2

Xxxxx Xxx. 4

Xxxxx Tox. 4

XXXX SE 2

Aquatic Xxxxx 1

Xxxxxxx Xxxxxxx 1

X351

X332

X302

X371 (xxxxxxx xxxxxx; xxxxxx, xxxxxxxxx)

X400

X410

XXX08

XXX07

XXX09

Xxx

X351

X332

X302

X371 (nervový xxxxxx; xxxxxx, inhalační)

H410

inhalační: XXX = 1,4 xx/x (xxxxx xxxx xxxx)

xxxxxx: XXX = 550 mg/kg XX

X = 10

X = 10“

„616-014-00-0

xxxxx-xx-xxxx; xxxxxxxxxxxxxxxxxx, xxxxx(xxxxxx)xxxxxxxxx

202-496-6

96-29-7

Xxxx. 1X

Xxxxx Xxx. 4

Xxxxx Xxx. 3

XXXX SE 3

XXXX XX 1

XXXX XX 2

Xxxx Xxxxx. 2

Xxx Dam. 1

Skin Xxxx. 1

H350

H312

H301

H336

H370 (horní xxxxxxx xxxxx)

X373 (xxxxxx xxxx)

X315

X318

X317

XXX08

XXX06

XXX05

Xxx

X350

X312

X301

X336

X370 (xxxxx xxxxxxx xxxxx)

X373 (xxxxxx xxxx)

X315

X318

X317

xxxxxxxx: XXX = 1&xxxx;100 xx/xx XX xxxxxx: XXX = 100 xx/xx TH“

„617-006-00-X

bis(α,α-dimethylbenzyl)peroxid

201-279-3

80-43-3

Org. Xxxxx. X

Xxxx. 1X

Xxxx Xxxxx. 2

Xxx Irrit. 2

Xxxxxxx Xxxxxxx 2

H242

H360D

H315

H319

H411

GHS02

GHS08

GHS07

GHS09

Dgr

H242

H360D

H315

H319

H411“

3)

položky odpovídající xxxxxxxxx číslům 601-064-00-8 x 607-693-00-4 xx xxxxxxx.